Vertex (VRTX) PT Lifted to $180 at Piper Jaffray as KALYDECO and ORKAMBI Both Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/1/2026
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
- Dollar pushes higher, yen sinks to 40-year low
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
- Citi says bearish flows are building in Nasdaq and S&P 500
- Patrick and LCI Industries to merge in all-stock deal
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
- DISH DBS files prepackaged chapter 11 to repay debt, wind down wireless
- Boeing commercial jet deliveries and production disrupted by widespread IT outage - Air Current
- Cantor Fitzgerald Starts Forward Industries (FWDI) at Overweight
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
Baird Positive on First Quarter of Vertex (VRTX) Orkambi Sales
October 29, 2015 6:58 AM EDTBaird analyst Brian Skorney reiterated an Outperform rating and $160 price target on Vertex (NASDAQ: VRTX) following results saying they are bullish on first quarter of Orkambi sales.
Skorney commented, "Right off the bat, Orkambi commanded ~35% of the patients eligible for treatment, according... More
Vertex Pharma (VRTX) Misses Q3 EPS by 9c
October 28, 2015 4:02 PM EDTVertex Pharma (NASDAQ: VRTX) reported Q3 EPS of ($0.39), $0.09 worse than the analyst estimate of ($0.30). Revenue for the quarter came in at $309.8 million versus the consensus estimate of $245.84 million.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
... More